EMG
NTLA icon

ETF Managers Group’s Intellia Therapeutics NTLA Stock Holding History

ETF Managers Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,663
Closed -$979K – 779
2022
Q2 		$979K Buy
+18,663
New +$948K 0.03% 234

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ETF Managers Group's NTLA Position: Q3 2022 in Review

ETF Managers Group sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 18,663 shares — an estimated $979K sold.

ETF Managers Group first reported a position in NTLA in Q2 2022 and held it in 1 quarter. The position peaked at $979K in Q2 2022. 321 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • ETF Managers Group reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • ETF Managers Group sold 18,663 Intellia Therapeutics shares in Q3 2022, an estimated $979K.
  • ETF Managers Group first reported a position in Intellia Therapeutics in Q2 2022 and held it in 1 quarter.
  • ETF Managers Group's Intellia Therapeutics position peaked at $979K in Q2 2022.
  • 321 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.